Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

Conditions

• Chronic Lymphocytic Leukemia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL

Key Dates

First listed

Dec 17, 2025

Start date

Dec 31, 2025

Status verified

Jul 2026

Primary completion

Dec 31, 2029

Completion

Dec 31, 2029

Study Design

Enrollment

50 participants (estimated)

Arms

• Arm: patients with CLL
  no control group or comparator involved

Primary Outcome Measure

Time to treatment discontinuation [ Time Frame: up to 25 months ]

Central Contacts

• AstraZeneca Clinical Study Information Center
  1-877-240-9479
  [email protected]

Find similar trials

Related Studies

• A Long-term Extension Study of PCI-32765 (Ibrutinib)
  PHASE3 · Recruiting · Janssen Research & Development, LLC · Orange, California
• Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
  PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
  Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
• Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
  PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas